BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv4.7.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.mdtechcouncil.com/membership/events
X-WR-CALDESC:Events for 
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230823T110000
DTEND;TZID=America/New_York:20230823T120000
DTSTAMP:20260415T114351
CREATED:20230921T154217Z
LAST-MODIFIED:20230921T154217Z
UID:3999-1692788400-1692792000@www.mdtechcouncil.com
SUMMARY:NCI Technology Opportunities Webinar: GPC1 as a New Therapeutic Target in Pancreatic Cancer: Development of Antibodies and CAR-T
DESCRIPTION:Updated Registration Link:  https://cbiit.webex.com/weblink/register/rd3e62547e5223e106861c6ec6ff496a6 \nRegister to attend a free NIH webinar. Attendees will learn about a new targeted immunotherapy pancreatic cancer treatment centered on the Glypican-1 (GPC1) cell surface heparan sulfate proteoglycan protein which is overexpressed in pancreatic cancer. The webinar will be presented by Dr. Mitchell Ho\, Deputy Chief\, NCI Laboratory of Molecular Biology. \nWebinar overview: The inventors will discuss the development of their novel Chimeric Antigen Receptors (CARs) specific for GPC1 that include short Immunoglobulin subclass 4 (IgG4) hinge sequences between the extracellular antigen recognition domain and the transmembrane domain. Hinge changes in CAR design can achieve the threshold of antigen density required for optimal CAR-T cell activity. Specifically\, the optimized GPC1-IgG4 hinge CARs show rapid and complete tumor regression in mouse models. \n
URL:https://www.mdtechcouncil.com/membership/events/calendar/nci-technology-opportunities-webinar-gpc1-as-a-new-therapeutic-target-in-pancreatic-cancer-development-of-antibodies-and-car-t-2/
LOCATION:Virtual Event
END:VEVENT
END:VCALENDAR